{"transactions":[{"id":4627795,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21760,"kind":"person","name":"Tamayo Louis Edward","position":1,"cik":"0002083206","reported_name":"Tamayo Louis Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-28T21:15:12.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":54750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":54750,"derivative":{"exercise_price":3.39,"expiration_date":"2036-09-23","underlying":"Common Stock","underlying_shares":54750},"source":{"system":"sec-edgar","filing":"0002083206-26-000009","document":"form4-09282026_050908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2083206/000208320626000009/form4-09282026_050908.xml","form_type":"4"}},{"id":4627797,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":33740,"kind":"person","name":"Bhalla Narinder Pal","position":1,"cik":"0002109299","reported_name":"Bhalla Narinder Pal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-28T21:15:10.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":54750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":54750,"derivative":{"exercise_price":3.39,"expiration_date":"2036-09-23","underlying":"Common Stock","underlying_shares":54750},"source":{"system":"sec-edgar","filing":"0002109299-26-000009","document":"form4-09282026_050906.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2109299/000210929926000009/form4-09282026_050906.xml","form_type":"4"}},{"id":4627796,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":33740,"kind":"person","name":"Bhalla Narinder Pal","position":1,"cik":"0002109299","reported_name":"Bhalla Narinder Pal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:15:10.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":2714,"price":3.579,"value":9713.406,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 49,500 Restricted Stock Units."}],"balance_after":84908,"source":{"system":"sec-edgar","filing":"0002109299-26-000009","document":"form4-09282026_050906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2109299/000210929926000009/form4-09282026_050906.xml","form_type":"4"}},{"id":4627799,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-28T21:15:08.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":54750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":54750,"derivative":{"exercise_price":3.39,"expiration_date":"2036-09-23","underlying":"Common Stock","underlying_shares":54750},"source":{"system":"sec-edgar","filing":"0002024096-26-000015","document":"form4-09282026_050904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000015/form4-09282026_050904.xml","form_type":"4"}},{"id":4627798,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:15:08.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":2110,"price":2.644,"value":5578.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 97,026 Restricted Stock Units."}],"balance_after":138288,"source":{"system":"sec-edgar","filing":"0002024096-26-000015","document":"form4-09282026_050904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000015/form4-09282026_050904.xml","form_type":"4"}},{"id":4627794,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-28T21:15:06.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":145500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":145500,"derivative":{"exercise_price":3.39,"expiration_date":"2036-09-23","underlying":"Common Stock","underlying_shares":145500},"source":{"system":"sec-edgar","filing":"0001995218-26-000017","document":"form4-09282026_050901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1995218/000199521826000017/form4-09282026_050901.xml","form_type":"4"}},{"id":4627793,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:15:06.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":2306,"price":2.644,"value":6097.064,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 242,911 Restricted Stock Units."}],"balance_after":376778,"source":{"system":"sec-edgar","filing":"0001995218-26-000017","document":"form4-09282026_050901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1995218/000199521826000017/form4-09282026_050901.xml","form_type":"4"}},{"id":681799,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21760,"kind":"person","name":"Tamayo Louis Edward","position":1,"cik":"0002083206","reported_name":"Tamayo Louis Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T21:00:13.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":4117,"price":4.9071,"value":20202.5307,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 78,415 Restricted Stock Units."}],"balance_after":92907,"source":{"system":"sec-edgar","filing":"0002083206-26-000007","document":"form4-08192026_050809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2083206/000208320626000007/form4-08192026_050809.xml","form_type":"4"}},{"id":680749,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-19T21:00:11.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":3345,"price":4.9512,"value":16561.764,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 242,911 Restricted Stock Units."}],"balance_after":374472,"source":{"system":"sec-edgar","filing":"0001995218-26-000015","document":"form4-08192026_050805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000015/form4-08192026_050805.xml","form_type":"4"}},{"id":681738,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-08-19T21:00:08.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":1304,"price":4.9571,"value":6464.0584,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.94 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 97,026 Restricted Stock Units."}],"balance_after":136178,"source":{"system":"sec-edgar","filing":"0002024096-26-000013","document":"form4-08192026_050801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000013/form4-08192026_050801.xml","form_type":"4"}},{"id":721631,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21760,"kind":"person","name":"Tamayo Louis Edward","position":1,"cik":"0002083206","reported_name":"Tamayo Louis Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-01T22:49:38.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":4641,"price":4.49,"value":20838.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of performance Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.33 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 89,665 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":97024,"source":{"system":"sec-edgar","filing":"0002083206-26-000005","document":"form4-07012026_100733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2083206/000208320626000005/form4-07012026_100733.xml","form_type":"4"}},{"id":721630,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21760,"kind":"person","name":"Tamayo Louis Edward","position":1,"cik":"0002083206","reported_name":"Tamayo Louis Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-01T22:49:38.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":101665,"source":{"system":"sec-edgar","filing":"0002083206-26-000005","document":"form4-07012026_100733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2083206/000208320626000005/form4-07012026_100733.xml","form_type":"4"}},{"id":721572,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-01T22:49:07.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":4666,"price":4.48,"value":20903.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of performance Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.35 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 100,621 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":137482,"source":{"system":"sec-edgar","filing":"0002024096-26-000011","document":"form4-07012026_100702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000011/form4-07012026_100702.xml","form_type":"4"}},{"id":721571,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-01T22:49:07.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":12060,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":142148,"source":{"system":"sec-edgar","filing":"0002024096-26-000011","document":"form4-07012026_100702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000011/form4-07012026_100702.xml","form_type":"4"}},{"id":720539,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":33740,"kind":"person","name":"Bhalla Narinder Pal","position":1,"cik":"0002109299","reported_name":"Bhalla Narinder Pal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-01T22:48:24.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":22306,"price":4.42,"value":98592.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of performance Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.341 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 49,500 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":82194,"source":{"system":"sec-edgar","filing":"0002109299-26-000007","document":"form4-07012026_100718.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000210929926000007/form4-07012026_100718.xml","form_type":"4"}},{"id":720538,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":33740,"kind":"person","name":"Bhalla Narinder Pal","position":1,"cik":"0002109299","reported_name":"Bhalla Narinder Pal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-01T22:48:24.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":104500,"source":{"system":"sec-edgar","filing":"0002109299-26-000007","document":"form4-07012026_100718.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000210929926000007/form4-07012026_100718.xml","form_type":"4"}},{"id":720536,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-01T22:47:19.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":25947,"price":4.48,"value":116242.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of performance Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.3402 to $4.7507. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 252,130 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":377817,"source":{"system":"sec-edgar","filing":"0001995218-26-000013","document":"form4-07012026_100715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000013/form4-07012026_100715.xml","form_type":"4"}},{"id":720535,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-01T22:47:19.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":403764,"source":{"system":"sec-edgar","filing":"0001995218-26-000013","document":"form4-07012026_100715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000013/form4-07012026_100715.xml","form_type":"4"}},{"id":723929,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34802,"kind":"person","name":"Altschuler Steven","position":1,"cik":"0001458116","reported_name":"Altschuler Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-29T20:45:56.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date."}],"balance_after":35000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-24","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001458116-26-000002","document":"form4-06292026_080651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1458116/000145811626000002/form4-06292026_080651.xml","form_type":"4"}},{"id":723674,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-29T20:45:14.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date."}],"balance_after":35000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-24","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001722234-26-000002","document":"form4-06292026_080602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722234/000172223426000002/form4-06292026_080602.xml","form_type":"4"}},{"id":723594,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34711,"kind":"person","name":"COOPERSTONE BRENDA","position":1,"cik":"0001931514","reported_name":"COOPERSTONE BRENDA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-29T20:44:26.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date."}],"balance_after":35000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-24","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001931514-26-000002","document":"form4-06292026_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000193151426000002/form4-06292026_080620.xml","form_type":"4"}},{"id":723861,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34785,"kind":"person","name":"DIAZ REINALDO M","position":1,"cik":"0001250086","reported_name":"DIAZ REINALDO M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-29T20:43:29.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date."}],"balance_after":35000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-24","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001250086-26-000002","document":"form4-06292026_080624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250086/000125008626000002/form4-06292026_080624.xml","form_type":"4"}},{"id":723633,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-29T20:42:45.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date."}],"balance_after":35000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-24","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001849458-26-000001","document":"form4-06292026_080640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1849458/000184945826000001/form4-06292026_080640.xml","form_type":"4"}},{"id":724131,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34846,"kind":"person","name":"Van Hauwermeiren Timothy","position":1,"cik":"0001816206","reported_name":"Van Hauwermeiren Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-29T20:41:45.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date."}],"balance_after":35000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-24","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001816206-26-000005","document":"form4-06292026_080640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816206/000181620626000005/form4-06292026_080640.xml","form_type":"4"}},{"id":723837,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34654,"kind":"person","name":"CHOLMONDELEY PAULA H","position":1,"cik":"0001193675","reported_name":"CHOLMONDELEY PAULA H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-29T20:40:36.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date."}],"balance_after":35000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-24","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193675-26-000002","document":"form4-06292026_080630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1193675/000119367526000002/form4-06292026_080630.xml","form_type":"4"}},{"id":770258,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:30:17.000Z","date":"2026-05-18","kind":"sale","planned":false,"acquired":false,"shares":1302,"price":5.074,"value":6606.348,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $5.06 to $5.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 100,621 Restricted Stock Units."}],"balance_after":130088,"source":{"system":"sec-edgar","filing":"0002024096-26-000009","document":"form4-05202026_040507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000009/form4-05202026_040507.xml","form_type":"4"}},{"id":769324,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:30:12.000Z","date":"2026-05-18","kind":"sale","planned":false,"acquired":false,"shares":3342,"price":5.0649,"value":16926.8958,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $5.03 to $5.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 252,130 Restricted Stock Units."}],"balance_after":336764,"source":{"system":"sec-edgar","filing":"0001995218-26-000011","document":"form4-05202026_040505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000011/form4-05202026_040505.xml","form_type":"4"}},{"id":796909,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-30T20:01:55.000Z","date":"2026-04-28","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service."}],"balance_after":50000,"derivative":{"exercise_price":5.81,"expiration_date":"2036-04-27","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001777421-26-000003","document":"form4-04302026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000177742126000003/form4-04302026_080451.xml","form_type":"4"}},{"id":813071,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-07T20:55:07.000Z","date":"2026-04-06","kind":"sale","planned":true,"acquired":false,"shares":55000,"price":5.6934,"value":313137.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $5.56 to $5.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 261,349 Restricted Stock Units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":340106,"source":{"system":"sec-edgar","filing":"0001995218-26-000009","document":"form4-04072026_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000009/form4-04072026_040401.xml","form_type":"4"}},{"id":836449,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-18T01:22:39.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":2623,"price":2.644,"value":6935.212,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 261,349 Restricted Stock Units."}],"balance_after":395106,"source":{"system":"sec-edgar","filing":"0001995218-26-000006","document":"form4-03182026_010332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000006/form4-03182026_010332.xml","form_type":"4"}},{"id":838635,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-18T01:14:36.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":5930,"price":2.644,"value":15678.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 104,216 restricted stock units."}],"balance_after":131390,"source":{"system":"sec-edgar","filing":"0002024096-26-000007","document":"form4-03182026_010330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000007/form4-03182026_010330.xml","form_type":"4"}},{"id":891005,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-20T22:05:09.000Z","date":"2026-02-18","kind":"sale","planned":false,"acquired":false,"shares":3016,"price":6.3972,"value":19293.9552,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $6.22 to $6.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 104,216 Restricted Stock Units."}],"balance_after":125460,"source":{"system":"sec-edgar","filing":"0002024096-26-000005","document":"form4-02202026_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000005/form4-02202026_050205.xml","form_type":"4"}},{"id":890056,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-20T22:05:07.000Z","date":"2026-02-18","kind":"sale","planned":false,"acquired":false,"shares":10173,"price":6.382,"value":64924.086,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $6.22 to $6.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 261,349 Restricted Stock Units."}],"balance_after":392483,"source":{"system":"sec-edgar","filing":"0001995218-26-000004","document":"form4-02202026_050203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000004/form4-02202026_050203.xml","form_type":"4"}},{"id":891004,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-20T22:05:04.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":721,"price":9.27,"value":6683.67,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 20, 2025, the reporting person filed a Form 4 which inadvertently reported that a sale to cover tax obligations occurred on August 18, 2025. In fact, as reported in this amendment, the sale occurred on November 18, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 47,733 RSUs."}],"balance_after":63476,"source":{"system":"sec-edgar","filing":"0002024096-26-000004","document":"form4a-02202026_050201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000004/form4a-02202026_050201.xml","form_type":"4/A","original_submission_date":"2025-11-20"}},{"id":900235,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":33740,"kind":"person","name":"Bhalla Narinder Pal","position":1,"cik":"0002109299","reported_name":"Bhalla Narinder Pal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-17T21:55:06.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":297000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on January 20, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":297000,"derivative":{"exercise_price":6.31,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":297000},"source":{"system":"sec-edgar","filing":"0002109299-26-000004","document":"form4-02172026_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000210929926000004/form4-02172026_040201.xml","form_type":"4"}},{"id":900234,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":33740,"kind":"person","name":"Bhalla Narinder Pal","position":1,"cik":"0002109299","reported_name":"Bhalla Narinder Pal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-17T21:55:06.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":49500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 49,500 RSUs."}],"balance_after":49500,"source":{"system":"sec-edgar","filing":"0002109299-26-000004","document":"form4-02172026_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000210929926000004/form4-02172026_040201.xml","form_type":"4"}},{"id":915628,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T22:00:12.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":646665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":646665,"derivative":{"exercise_price":7.27,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001995218-26-000002","document":"form4-02062026_050205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000002/form4-02062026_050205.xml","form_type":"4"}},{"id":915627,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-06T22:00:12.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":161665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 290,022 RSUs."}],"balance_after":402656,"source":{"system":"sec-edgar","filing":"0001995218-26-000002","document":"form4-02062026_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000002/form4-02062026_050205.xml","form_type":"4"}},{"id":916221,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T22:00:10.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":260000,"derivative":{"exercise_price":7.27,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0002024096-26-000002","document":"form4-02062026_050203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000002/form4-02062026_050203.xml","form_type":"4"}},{"id":916220,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-06T22:00:10.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 112,733 RSUs."}],"balance_after":128476,"source":{"system":"sec-edgar","filing":"0002024096-26-000002","document":"form4-02062026_050203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409626000002/form4-02062026_050203.xml","form_type":"4"}},{"id":916293,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21760,"kind":"person","name":"Tamayo Louis Edward","position":1,"cik":"0002083206","reported_name":"Tamayo Louis Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T22:00:09.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":226665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":226665,"derivative":{"exercise_price":7.27,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":226665},"source":{"system":"sec-edgar","filing":"0002083206-26-000002","document":"form4-02062026_050201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2083206/000208320626000002/form4-02062026_050201.xml","form_type":"4"}},{"id":916292,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21760,"kind":"person","name":"Tamayo Louis Edward","position":1,"cik":"0002083206","reported_name":"Tamayo Louis Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-06T22:00:09.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":44665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported securities are RSUs."}],"balance_after":89665,"source":{"system":"sec-edgar","filing":"0002083206-26-000002","document":"form4-02062026_050201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2083206/000208320626000002/form4-02062026_050201.xml","form_type":"4"}},{"id":992158,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-20T22:21:29.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":1127,"price":9.27,"value":10447.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 128,357 Restricted Stock Units."}],"balance_after":240991,"source":{"system":"sec-edgar","filing":"0001995218-25-000007","document":"form4-11202025_101125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521825000007/form4-11202025_101125.xml","form_type":"4"}},{"id":992157,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72797,"kind":"person","name":"Adler Eric","position":1,"cik":"0001994972","reported_name":"Adler Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-20T22:20:13.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":615,"price":9.27,"value":5701.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,866 RSUs."}],"balance_after":72646,"source":{"system":"sec-edgar","filing":"0001994972-25-000005","document":"form4-11202025_101109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199497225000005/form4-11202025_101109.xml","form_type":"4"}},{"id":992153,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72796,"kind":"person","name":"Robertson Jenny","position":1,"cik":"0001995009","reported_name":"Robertson Jenny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-11-20T22:18:07.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":549,"price":9.27,"value":5089.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 49,607 RSUs."}],"balance_after":68381,"source":{"system":"sec-edgar","filing":"0001995009-25-000005","document":"form4-11202025_101103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199500925000005/form4-11202025_101103.xml","form_type":"4"}},{"id":992728,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-11-20T22:14:54.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":721,"price":9.27,"value":6683.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 47,733 RSUs."}],"balance_after":63476,"source":{"system":"sec-edgar","filing":"0002024096-25-000005","document":"form4-11202025_101149.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409625000005/form4-11202025_101149.xml","form_type":"4"}},{"id":992707,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72831,"kind":"person","name":"See Tai Sandi","position":1,"cik":"0002009350","reported_name":"See Tai Sandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-11-20T17:19:10.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":386,"price":9.27,"value":3578.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 48,098 RSUs."}],"balance_after":65476,"source":{"system":"sec-edgar","filing":"0002009350-25-000005","document":"form4-11202025_101104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009350/000200935025000005/form4-11202025_101104.xml","form_type":"4"}},{"id":1016227,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72796,"kind":"person","name":"Robertson Jenny","position":1,"cik":"0001995009","reported_name":"Robertson Jenny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:28:53.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":40,"price":9.561,"value":382.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 51,092 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":68930,"source":{"system":"sec-edgar","filing":"0001995009-25-000003","document":"form4-10172025_111049.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199500925000003/form4-10172025_111049.xml","form_type":"4"}},{"id":1016226,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72796,"kind":"person","name":"Robertson Jenny","position":1,"cik":"0001995009","reported_name":"Robertson Jenny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:28:53.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":3486,"price":8.935,"value":31147.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":68970,"source":{"system":"sec-edgar","filing":"0001995009-25-000003","document":"form4-10172025_111049.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199500925000003/form4-10172025_111049.xml","form_type":"4"}},{"id":1016225,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72796,"kind":"person","name":"Robertson Jenny","position":1,"cik":"0001995009","reported_name":"Robertson Jenny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:28:53.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":9900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":72456,"source":{"system":"sec-edgar","filing":"0001995009-25-000003","document":"form4-10172025_111049.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199500925000003/form4-10172025_111049.xml","form_type":"4"}},{"id":1016994,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:28:16.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":24,"price":9.561,"value":229.464,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 49,687 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":64197,"source":{"system":"sec-edgar","filing":"0002024096-25-000003","document":"form4-10172025_111011.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409625000003/form4-10172025_111011.xml","form_type":"4"}},{"id":1016993,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:28:16.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":2091,"price":8.935,"value":18683.085,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":64221,"source":{"system":"sec-edgar","filing":"0002024096-25-000003","document":"form4-10172025_111011.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409625000003/form4-10172025_111011.xml","form_type":"4"}},{"id":1016992,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:28:16.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":5940,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":66312,"source":{"system":"sec-edgar","filing":"0002024096-25-000003","document":"form4-10172025_111011.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000202409625000003/form4-10172025_111011.xml","form_type":"4"}},{"id":1016224,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72797,"kind":"person","name":"Adler Eric","position":1,"cik":"0001994972","reported_name":"Adler Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:26:52.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":38,"price":9.561,"value":363.318,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 60,546 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":73261,"source":{"system":"sec-edgar","filing":"0001994972-25-000003","document":"form4-10172025_111047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199497225000003/form4-10172025_111047.xml","form_type":"4"}},{"id":1016223,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72797,"kind":"person","name":"Adler Eric","position":1,"cik":"0001994972","reported_name":"Adler Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:26:52.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":3344,"price":8.935,"value":29878.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":73299,"source":{"system":"sec-edgar","filing":"0001994972-25-000003","document":"form4-10172025_111047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199497225000003/form4-10172025_111047.xml","form_type":"4"}},{"id":1016222,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72797,"kind":"person","name":"Adler Eric","position":1,"cik":"0001994972","reported_name":"Adler Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:26:52.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":9570,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":76643,"source":{"system":"sec-edgar","filing":"0001994972-25-000003","document":"form4-10172025_111047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199497225000003/form4-10172025_111047.xml","form_type":"4"}},{"id":1016221,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:26:05.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":148,"price":9.561,"value":1415.028,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 131,092 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":242118,"source":{"system":"sec-edgar","filing":"0001995218-25-000005","document":"form4-10172025_111000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521825000005/form4-10172025_111000.xml","form_type":"4"}},{"id":1016220,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:26:05.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":12985,"price":8.935,"value":116020.975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":242266,"source":{"system":"sec-edgar","filing":"0001995218-25-000005","document":"form4-10172025_111000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521825000005/form4-10172025_111000.xml","form_type":"4"}},{"id":1016219,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:26:05.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":255251,"source":{"system":"sec-edgar","filing":"0001995218-25-000005","document":"form4-10172025_111000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521825000005/form4-10172025_111000.xml","form_type":"4"}},{"id":1016964,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72831,"kind":"person","name":"See Tai Sandi","position":1,"cik":"0002009350","reported_name":"See Tai Sandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-10-17T19:29:33.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":44,"price":9.561,"value":420.684,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 49,138 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":65862,"source":{"system":"sec-edgar","filing":"0002009350-25-000003","document":"form4-10172025_111028.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2009350/000200935025000003/form4-10172025_111028.xml","form_type":"4"}},{"id":1016963,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72831,"kind":"person","name":"See Tai Sandi","position":1,"cik":"0002009350","reported_name":"See Tai Sandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-10-17T19:29:33.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":3844,"price":8.935,"value":34346.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":65906,"source":{"system":"sec-edgar","filing":"0002009350-25-000003","document":"form4-10172025_111028.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009350/000200935025000003/form4-10172025_111028.xml","form_type":"4"}},{"id":1016962,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72831,"kind":"person","name":"See Tai Sandi","position":1,"cik":"0002009350","reported_name":"See Tai Sandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-10-17T19:29:33.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":10890,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":69750,"source":{"system":"sec-edgar","filing":"0002009350-25-000003","document":"form4-10172025_111028.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009350/000200935025000003/form4-10172025_111028.xml","form_type":"4"}},{"id":1038934,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-16T21:30:06.000Z","date":"2025-09-12","kind":"grant","planned":false,"acquired":true,"shares":2193,"price":2.644,"value":5798.292,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 131,092 Restricted Stock Units."}],"balance_after":222251,"source":{"system":"sec-edgar","filing":"0001995218-25-000003","document":"form4-09162025_050903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521825000003/form4-09162025_050903.xml","form_type":"4"}},{"id":1043649,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-10T20:59:33.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":1115,"price":4.668,"value":5204.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On August 20, 2025, the reporting person filed a Form 4 which inadvertently reported the disposition of 2,735 securities. In fact, as reported in this amendment, the reporting person disposed of 1,115 shares of Common Stock on August 18, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 131,092 Restricted Stock Units."}],"balance_after":220058,"source":{"system":"sec-edgar","filing":"0001415889-25-024104","document":"form4a-09102025_080929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925024104/form4a-09102025_080929.xml","form_type":"4/A","original_submission_date":"2025-08-20"}},{"id":1050208,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21760,"kind":"person","name":"Tamayo Louis Edward","position":1,"cik":"0002083206","reported_name":"Tamayo Louis Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-09-03T18:00:05.000Z","date":"2025-08-29","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on August 15, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":280000,"derivative":{"exercise_price":4.79,"expiration_date":"2035-08-28","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001415889-25-023491","document":"form4-09032025_020901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2083206/000141588925023491/form4-09032025_020901.xml","form_type":"4"}},{"id":1050207,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21760,"kind":"person","name":"Tamayo Louis Edward","position":1,"cik":"0002083206","reported_name":"Tamayo Louis Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-03T18:00:05.000Z","date":"2025-08-29","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on August 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported securities are RSUs."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001415889-25-023491","document":"form4-09032025_020901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2083206/000141588925023491/form4-09032025_020901.xml","form_type":"4"}},{"id":1060480,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-08-20T21:05:06.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":2848,"price":4.668,"value":13294.464,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 49,687 RSUs."}],"balance_after":60372,"source":{"system":"sec-edgar","filing":"0001415889-25-022479","document":"form4-08202025_090801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000141588925022479/form4-08202025_090801.xml","form_type":"4"}},{"id":1059804,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72796,"kind":"person","name":"Robertson Jenny","position":1,"cik":"0001995009","reported_name":"Robertson Jenny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-08-20T21:03:45.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":542,"price":4.668,"value":2530.056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 51,092 RSUs."}],"balance_after":62556,"source":{"system":"sec-edgar","filing":"0001415889-25-022477","document":"form4-08202025_090842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925022477/form4-08202025_090842.xml","form_type":"4"}},{"id":1059801,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72797,"kind":"person","name":"Adler Eric","position":1,"cik":"0001994972","reported_name":"Adler Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-20T21:02:15.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":608,"price":4.668,"value":2838.144,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 60,546 RSUs."}],"balance_after":67073,"source":{"system":"sec-edgar","filing":"0001415889-25-022475","document":"form4-08202025_090811.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925022475/form4-08202025_090811.xml","form_type":"4"}},{"id":1059800,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-20T21:00:18.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":2735,"price":4.668,"value":12766.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 131,092 RSUs."}],"balance_after":220058,"source":{"system":"sec-edgar","filing":"0001415889-25-022473","document":"form4-08202025_090813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925022473/form4-08202025_090813.xml","form_type":"4"}},{"id":1060463,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72831,"kind":"person","name":"See Tai Sandi","position":1,"cik":"0002009350","reported_name":"See Tai Sandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-08-20T16:58:23.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":382,"price":4.668,"value":1783.176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 49,138 RSUs."}],"balance_after":58860,"source":{"system":"sec-edgar","filing":"0001415889-25-022468","document":"form4-08202025_080818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009350/000141588925022468/form4-08202025_080818.xml","form_type":"4"}},{"id":1098911,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T21:00:20.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date."}],"balance_after":14583,"derivative":{"exercise_price":4.18,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":14583},"source":{"system":"sec-edgar","filing":"0001415889-25-018524","document":"form4-06302025_050616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1849458/000141588925018524/form4-06302025_050616.xml","form_type":"4"}},{"id":1099349,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34846,"kind":"person","name":"Van Hauwermeiren Timothy","position":1,"cik":"0001816206","reported_name":"Van Hauwermeiren Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T21:00:19.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":22916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date."}],"balance_after":22916,"derivative":{"exercise_price":4.18,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":22916},"source":{"system":"sec-edgar","filing":"0001415889-25-018523","document":"form4-06302025_050614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816206/000141588925018523/form4-06302025_050614.xml","form_type":"4"}},{"id":1099134,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34785,"kind":"person","name":"DIAZ REINALDO M","position":1,"cik":"0001250086","reported_name":"DIAZ REINALDO M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T21:00:15.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date."}],"balance_after":25000,"derivative":{"exercise_price":4.18,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-018522","document":"form4-06302025_050611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250086/000141588925018522/form4-06302025_050611.xml","form_type":"4"}},{"id":1098906,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34711,"kind":"person","name":"COOPERSTONE BRENDA","position":1,"cik":"0001931514","reported_name":"COOPERSTONE BRENDA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T21:00:14.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date."}],"balance_after":25000,"derivative":{"exercise_price":4.18,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-018521","document":"form4-06302025_050609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925018521/form4-06302025_050609.xml","form_type":"4"}},{"id":1099116,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34654,"kind":"person","name":"CHOLMONDELEY PAULA H","position":1,"cik":"0001193675","reported_name":"CHOLMONDELEY PAULA H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T21:00:10.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date."}],"balance_after":25000,"derivative":{"exercise_price":4.18,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-018520","document":"form4-06302025_050606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1193675/000141588925018520/form4-06302025_050606.xml","form_type":"4"}},{"id":1099217,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34802,"kind":"person","name":"Altschuler Steven","position":1,"cik":"0001458116","reported_name":"Altschuler Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T21:00:08.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date."}],"balance_after":25000,"derivative":{"exercise_price":4.18,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-018519","document":"form4-06302025_050604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1458116/000141588925018519/form4-06302025_050604.xml","form_type":"4"}},{"id":1098943,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T21:00:06.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date."}],"balance_after":25000,"derivative":{"exercise_price":4.18,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-018518","document":"form4-06302025_050601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722234/000141588925018518/form4-06302025_050601.xml","form_type":"4"}},{"id":1139911,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-20T21:00:15.000Z","date":"2025-05-16","kind":"sale","planned":false,"acquired":false,"shares":1074,"price":2.774,"value":2979.276,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 133,827 RSUs."}],"balance_after":221173,"source":{"system":"sec-edgar","filing":"0001415889-25-013819","document":"form4-05202025_050509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925013819/form4-05202025_050509.xml","form_type":"4"}},{"id":1139910,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72797,"kind":"person","name":"Adler Eric","position":1,"cik":"0001994972","reported_name":"Adler Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-05-20T21:00:14.000Z","date":"2025-05-16","kind":"sale","planned":false,"acquired":false,"shares":585,"price":2.774,"value":1622.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 62,226 RSUs."}],"balance_after":67681,"source":{"system":"sec-edgar","filing":"0001415889-25-013818","document":"form4-05202025_050506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925013818/form4-05202025_050506.xml","form_type":"4"}},{"id":1139909,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72796,"kind":"person","name":"Robertson Jenny","position":1,"cik":"0001995009","reported_name":"Robertson Jenny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-05-20T21:00:12.000Z","date":"2025-05-16","kind":"sale","planned":false,"acquired":false,"shares":521,"price":2.774,"value":1445.254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 52,577 restricted stock units."}],"balance_after":63098,"source":{"system":"sec-edgar","filing":"0001415889-25-013817","document":"form4-05202025_050504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925013817/form4-05202025_050504.xml","form_type":"4"}},{"id":1140705,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72831,"kind":"person","name":"See Tai Sandi","position":1,"cik":"0002009350","reported_name":"See Tai Sandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-05-20T17:00:11.000Z","date":"2025-05-16","kind":"sale","planned":false,"acquired":false,"shares":367,"price":2.774,"value":1018.058,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 50,178 RSUs."}],"balance_after":59242,"source":{"system":"sec-edgar","filing":"0001415889-25-013816","document":"form4-05202025_050501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009350/000141588925013816/form4-05202025_050501.xml","form_type":"4"}},{"id":1174849,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-04-09T21:48:02.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":5720,"price":2.61,"value":14929.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 57,500 restricted stock units."}],"balance_after":63220,"source":{"system":"sec-edgar","filing":"0001415889-25-010505","document":"form4-04092025_090458.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000141588925010505/form4-04092025_090458.xml","form_type":"4"}},{"id":1174519,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72796,"kind":"person","name":"Robertson Jenny","position":1,"cik":"0001995009","reported_name":"Robertson Jenny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-04-09T21:46:09.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":5720,"price":2.61,"value":14929.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 54,062 restricted stock units."}],"balance_after":63619,"source":{"system":"sec-edgar","filing":"0001415889-25-010503","document":"form4-04092025_090405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925010503/form4-04092025_090405.xml","form_type":"4"}},{"id":1174821,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72831,"kind":"person","name":"See Tai Sandi","position":1,"cik":"0002009350","reported_name":"See Tai Sandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-04-09T17:44:52.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":5720,"price":2.61,"value":14929.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 51,218 restricted stock units."}],"balance_after":59609,"source":{"system":"sec-edgar","filing":"0001415889-25-010501","document":"form4-04092025_090448.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009350/000141588925010501/form4-04092025_090448.xml","form_type":"4"}},{"id":1185839,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-01T23:58:17.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":2128,"price":2.61,"value":5554.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."}],"balance_after":222247,"source":{"system":"sec-edgar","filing":"0001415889-25-009450","document":"form4-04012025_110414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925009450/form4-04012025_110414.xml","form_type":"4"}},{"id":1252063,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-21T22:10:25.000Z","date":"2025-02-19","kind":"sale","planned":false,"acquired":false,"shares":4326,"price":4.413,"value":19090.638,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 136,562 RSUs."}],"balance_after":220119,"source":{"system":"sec-edgar","filing":"0001415889-25-005113","document":"form4-02212025_100221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925005113/form4-02212025_100221.xml","form_type":"4"}},{"id":1252064,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72797,"kind":"person","name":"Adler Eric","position":1,"cik":"0001994972","reported_name":"Adler Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-21T22:09:13.000Z","date":"2025-02-19","kind":"sale","planned":false,"acquired":false,"shares":2359,"price":4.413,"value":10410.267,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 63,906 RSUs."}],"balance_after":68266,"source":{"system":"sec-edgar","filing":"0001415889-25-005109","document":"form4-02212025_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925005109/form4-02212025_100209.xml","form_type":"4"}},{"id":1252062,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72796,"kind":"person","name":"Robertson Jenny","position":1,"cik":"0001995009","reported_name":"Robertson Jenny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-21T22:08:44.000Z","date":"2025-02-19","kind":"sale","planned":false,"acquired":false,"shares":2101,"price":4.413,"value":9271.713,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 54,062 RSUs."}],"balance_after":57899,"source":{"system":"sec-edgar","filing":"0001415889-25-005108","document":"form4-02212025_100240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925005108/form4-02212025_100240.xml","form_type":"4"}},{"id":1253382,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72831,"kind":"person","name":"See Tai Sandi","position":1,"cik":"0002009350","reported_name":"See Tai Sandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-02-21T17:09:42.000Z","date":"2025-02-19","kind":"sale","planned":false,"acquired":false,"shares":1486,"price":4.413,"value":6557.718,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 51,218 RSUs."}],"balance_after":53889,"source":{"system":"sec-edgar","filing":"0001415889-25-005110","document":"form4-02212025_100238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009350/000141588925005110/form4-02212025_100238.xml","form_type":"4"}},{"id":1297961,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":83998,"kind":"person","name":"Rasbach Kyle","position":1,"cik":"0002050086","reported_name":"Rasbach Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-22T16:55:05.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":245250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on December 18, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":245250,"derivative":{"exercise_price":5.07,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":245250},"source":{"system":"sec-edgar","filing":"0001415889-25-001859","document":"form4-01222025_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050086/000141588925001859/form4-01222025_040101.xml","form_type":"4"}},{"id":1297960,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":83998,"kind":"person","name":"Rasbach Kyle","position":1,"cik":"0002050086","reported_name":"Rasbach Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-22T16:55:05.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":40875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported securities are RSUs."}],"balance_after":40875,"source":{"system":"sec-edgar","filing":"0001415889-25-001859","document":"form4-01222025_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050086/000141588925001859/form4-01222025_040101.xml","form_type":"4"}},{"id":1304801,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T21:55:14.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":207500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on January 7, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":207500,"derivative":{"exercise_price":7.33,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":207500},"source":{"system":"sec-edgar","filing":"0001415889-25-001287","document":"form4-01102025_040110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925001287/form4-01102025_040110.xml","form_type":"4"}},{"id":1304800,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:55:14.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":103750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 147,500 RSUs."}],"balance_after":224445,"source":{"system":"sec-edgar","filing":"0001415889-25-001287","document":"form4-01102025_040110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925001287/form4-01102025_040110.xml","form_type":"4"}},{"id":1305504,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T21:55:13.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on January 7, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":52500,"derivative":{"exercise_price":7.33,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001415889-25-001286","document":"form4-01102025_040108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000141588925001286/form4-01102025_040108.xml","form_type":"4"}},{"id":1305503,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21723,"kind":"person","name":"Otero Jose Manuel","position":1,"cik":"0002024096","reported_name":"Otero Jose Manuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:55:13.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported securities are RSUs."}],"balance_after":57500,"source":{"system":"sec-edgar","filing":"0001415889-25-001286","document":"form4-01102025_040108.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024096/000141588925001286/form4-01102025_040108.xml","form_type":"4"}},{"id":1304799,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72796,"kind":"person","name":"Robertson Jenny","position":1,"cik":"0001995009","reported_name":"Robertson Jenny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Admin Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T21:55:10.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":72500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on January 7, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":72500,"derivative":{"exercise_price":7.33,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":72500},"source":{"system":"sec-edgar","filing":"0001415889-25-001285","document":"form4-01102025_040106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925001285/form4-01102025_040106.xml","form_type":"4"}},{"id":1304798,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72796,"kind":"person","name":"Robertson Jenny","position":1,"cik":"0001995009","reported_name":"Robertson Jenny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Admin Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:55:10.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":36250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported securities are RSUs."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001415889-25-001285","document":"form4-01102025_040106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925001285/form4-01102025_040106.xml","form_type":"4"}},{"id":1304797,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72797,"kind":"person","name":"Adler Eric","position":1,"cik":"0001994972","reported_name":"Adler Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T21:55:04.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on January 7, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":87500,"derivative":{"exercise_price":7.33,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001415889-25-001283","document":"form4-01102025_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925001283/form4-01102025_040101.xml","form_type":"4"}},{"id":1304796,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":72797,"kind":"person","name":"Adler Eric","position":1,"cik":"0001994972","reported_name":"Adler Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:55:04.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":43750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported securities are RSUs."}],"balance_after":70625,"source":{"system":"sec-edgar","filing":"0001415889-25-001283","document":"form4-01102025_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925001283/form4-01102025_040101.xml","form_type":"4"}}],"next_cursor":"2025-01-10T21:55:04.000000Z,1304796"}